Smac Mimetics in Combination with TRAIL Selectively Target Cancer Stem Cells in Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma is a common malignancy in Southern China. After radiotherapy and chemotherapy, a considerable proportion of patients with nasopharyngeal carcinoma suffered tumor relapse and metastasis. Cancer stem cells (CSC) have been shown with resistance against therapies and thus considered as the initiator of recurrence and metastasis in tumors, where the antiapoptotic property of CSCs play an important role. Smac/DIABLO is an inverse regulator for the inhibitors of apoptosis protein family (IAP), which have been involved in apoptosis. Here, the effects of Smac mimetics on the CSCs of nasopharyngeal carcinoma were studied both in vitro and in vivo, using two clones of nasopharyngeal carcinoma cell line CNE2 as models. We found that one of the clones, S18, had CSC-like properties and IAPs were overexpressed. The combination of Smac mimetics and TNF-related apoptosis-inducing ligand (TRAIL) can reduce the percentage of SP cells and inhibit the colony- and sphere-forming abilities of S18 cells, indicating their ability to attenuate the CSCs. Moreover, in a nasopharyngeal carcinoma xenograft model, the administration of Smac mimetics in combination with TRAIL also led to the elimination of nasopharyngeal carcinoma stem cells. Furthermore, the Smac mimetics in combination with TRAIL induced the degradation of cIAP1 and XIAP and thus induced apoptosis in vitro and in vivo. Taken together, our data show that Smac mimetics exerted an antitumor effect on nasopharyngeal carcinoma cancer stem cells, and this combination treatment should be considered as a promising strategy for the treatment of nasopharyngeal carcinoma. Mol Cancer Ther; 12(9); 1728–37. ©2013 AACR.

[1]  A. Gibson.  The European Society for Medical Oncology (ESMO) , 2019, Annals of Oncology.

[2]  B. Leber,et al.  Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells , 2012, Cell.

[3]  S. Keir,et al.  Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program , 2012, Pediatric blood & cancer.

[4]  Ronald D. Alvarez,et al.  Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer , 2011, Clinical Cancer Research.

[5]  Shazib Pervaiz,et al.  Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. , 2011, Biochimica et biophysica acta.

[6]  S. Rottey,et al.  Modern treatment for nasopharyngeal carcinoma: current status and prospects , 2011, Current opinion in oncology.

[7]  Tao Zhang,et al.  A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. , 2011, Journal of medicinal chemistry.

[8]  Shaomeng Wang,et al.  Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment , 2011, Molecular Cancer Therapeutics.

[9]  I. Ng,et al.  Lupeol targets liver tumor‐initiating cells through phosphatase and tensin homolog modulation , 2011, Hepatology.

[10]  J. Baselga,et al.  TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. , 2010, Cancer cell.

[11]  D. McConkey,et al.  Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells , 2010, Cancer biology & therapy.

[12]  Johannes A. Langendijk,et al.  Current treatment options for recurrent nasopharyngeal cancer , 2010, European Archives of Oto-Rhino-Laryngology.

[13]  J. Moffat,et al.  Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens , 2010, EMBO molecular medicine.

[14]  J. Rich,et al.  Potential therapeutic implications of cancer stem cells in glioblastoma. , 2010, Biochemical pharmacology.

[15]  H. Kashkar.  X-linked Inhibitor of Apoptosis: A Chemoresistance Factor or a Hollow Promise , 2010, Clinical Cancer Research.

[16]  R. Herbst,et al.  Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Tao Zhang,et al.  Sulforaphane, a Dietary Component of Broccoli/Broccoli Sprouts, Inhibits Breast Cancer Stem Cells , 2010, Clinical Cancer Research.

[18]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[19]  Erwin G. Van Meir,et al.  Tumor initiating cells in malignant gliomas: biology and implications for therapy , 2009, Journal of Molecular Medicine.

[20]  Shaomeng Wang,et al.  SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. , 2008, Cancer research.

[21]  F. Kruyt.  TRAIL and cancer therapy. , 2008, Cancer letters.

[22]  S. Srinivasula,et al.  IAPs: what's in a name? , 2008, Molecular cell.

[23]  David L. Vaux,et al.  IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis , 2007, Cell.

[24]  J. Minna,et al.  Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. , 2007, Cancer cell.

[25]  Y. Zeng,et al.  Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. , 2007, Cancer research.

[26]  L. Gianni,et al.  Targeting TRAIL Agonistic Receptors for Cancer Therapy , 2007, Clinical Cancer Research.

[27]  M. Clarke,et al.  Cancer stem cells: models and concepts. , 2007, Annual review of medicine.

[28]  Shaomeng Wang,et al.  Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. , 2006, Journal of medicinal chemistry.

[29]  B. Berghuis,et al.  Preparing the "soil": the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. , 2006, Cancer research.

[30]  W. Fairbrother,et al.  Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs. , 2006, ACS chemical biology.

[31]  G. Salvesen,et al.  Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family , 2006, EMBO reports.

[32]  S. Forbes,et al.  Side population (SP) cells: Taking center stage in regeneration and liver cancer? , 2006, Hepatology.

[33]  T. Utsunomiya,et al.  Characterization of a Side Population of Cancer Cells from Human Gastrointestinal System , 2006, Stem cells.

[34]  G. Salvesen,et al.  The Human Anti-apoptotic Proteins cIAP1 and cIAP2 Bind but Do Not Inhibit Caspases* , 2006, Journal of Biological Chemistry.

[35]  N. Munshi,et al.  Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). , 2004, Blood.

[36]  Xiaodong Wang,et al.  A Small Molecule Smac Mimic Potentiates TRAIL- and TNFα-Mediated Cell Death , 2004, Science.

[37]  Shaomeng Wang,et al.  Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. , 2004, Journal of medicinal chemistry.

[38]  Jun Ma,et al.  Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: A pooled data analysis of two phase III trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Chunying Du,et al.  Smac/DIABLO Selectively Reduces the Levels of c-IAP1 and c-IAP2 but Not That of XIAP and Livin in HeLa Cells* , 2004, Journal of Biological Chemistry.

[40]  Wafik S El-Deiry,et al.  TRAIL and apoptosis induction by TNF-family death receptors , 2003, Oncogene.

[41]  G. Salvesen,et al.  Apoptosis: IAP proteins: blocking the road to death's door , 2002, Nature Reviews Molecular Cell Biology.

[42]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[43]  S. Chan.  Aetiology of Nasopharyngeal Carcinoma , 1976, The Lancet.

[44]  Pelayo Vilar,et al.  Nasopharyngeal Carcinoma , 1966 .

[45]  S. Fulda,et al.  Apoptosis signaling in cancer stem cells. , 2010, The international journal of biochemistry & cell biology.

[46]  C. Hao,et al.  TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. , 2009, Reviews on recent clinical trials.

[47]  Vinay Tergaonkar,et al.  IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. , 2007, Cell.

[48]  H. Sugerman,et al.  Association between Incident Cancer and Subsequent Stroke , 2015, Annals of neurology.

[49]  Xiaodong Wang,et al.  A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. , 2004, Science.

[50]  Michael Weller,et al.  Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo , 2002, Nature Medicine.